In today’s recent session, 0.58 million shares of the Arcutis Biotherapeutics Inc (NASDAQ:ARQT) have been traded, and its beta is 1.16. Most recently the company’s share price was $8.94, and it changed around $0.45 or 5.27% from the last close, which brings the market valuation of the company to $1.03B. ARQT at last check was trading at a discount to its 52-week high of $13.17, offering almost -47.32% off that amount. The share price’s 52-week low was $1.76, which indicates that the recent value has risen by an impressive 80.31% since then. We note from Arcutis Biotherapeutics Inc’s average daily trading volume that its 3-month average coming to 3.02 million.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Instantly ARQT has been showing a green trend so far today with a performance of 5.27% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently up 176.70% year-to-date, but still up 3.56% over the last five days. On the other hand, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is -9.90% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $31, which translates to bulls needing to increase their stock price by 71.16% from its current value. Analyst projections state that ARQT is forecast to be at a low of $18 and a high of $51.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Arcutis Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 245.08 percent over the past six months and at a 57.67% annual growth rate that is well above the industry average of 15.20%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -48.07%. Arcutis Biotherapeutics Inc earnings are expected to increase by 55.07% in 2024, but the outlook is positive 9.80% per year for the next five years.
ARQT Dividends
Arcutis Biotherapeutics Inc’s next quarterly earnings report is expected to be released in July.
